Delving into the Latest Updates on Iodine[131I] Metuximab with Synapse

Overview

Basic Info

Drug Type

Radiolabeled antibody, Therapeutic radiopharmaceuticals

Synonyms

碘(131I)美妥昔单抗, Licartin, 利卡汀

Target

BSG

Mechanism

BSG inhibitors(Basigin inhibitors), Ionising radiation emitters

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Hepatocellular Carcinoma

Inactive Indication-

Originator Organization

Chengdu Huasun Biotechnology Co. Ltd.

Active Organization

Chengdu Huasun Biotechnology Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (12 Oct 2006),

Hepatocellular Carcinoma

Regulation-

Login to view timeline

Structure

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

This clinical trial is designed to provide one kind of modalities for preventing the recurrence and metastasis of PLC. If the expected therapeutic efficacy is achieved, it shall contribute actively to boosting the therapeutic level of PLC, prolonging its recurrent time and enhancing its overall survival. And it may also raise the clinical recognition of this technology, promote its clinical applications and generate excellent social reputations and economic returns.

Start Date01 Jan 2012

Sponsor / Collaborator

Tianjin Cancer Institute

100 Clinical Results associated with Iodine[131I] Metuximab

Login to view more data

100 Translational Medicine associated with Iodine[131I] Metuximab

Login to view more data

100 Patents (Medical) associated with Iodine[131I] Metuximab

Login to view more data

19

Literatures (Medical) associated with Iodine[131I] Metuximab

01 Jan 2022·Frontiers in oncology

Analysis of factors influencing the distribution of 131-I in combined treatment of Licartin with transcatheter arterial chemoembolization in primary hepatic carcinoma.

Article

Author: Zhu, Jia-Lun ; Tang, Ming ; Liu, Peng-Jie ; Lv, Juan ; Li, Wen-Liang ; Chen, Fu-Kun ; Li, Jia-Yu

ObjectiveTo analyze the factors influencing the distribution of 131-I in the liver of patients with advanced hepatic carcinoma treated with the combination of Licartin (¹³¹I Metuximab) and transcatheter arterial chemoembolization (TACE). This study provides a reference and basis for the clinic on how to choose the best time for the treatment of Licartin and how to reduce other possible factors affecting the role of Licartin.MethodsData from 41 patients with advanced hepatic carcinoma treated with the combination of Licartin and TACE in the Interventional Department of our hospital from March 2014 to December 2020 were collected. This included general characteristics, history of open and interventional surgery, interval between the last interventional surgery and the Licartin treatment, selected arteries in the Licartin perfusion, and 131-I distribution in the liver. Regression analysis was conducted to investigate the factors affecting the distribution of ¹³¹I in the liver.ResultsIn 14 cases (34.1%), 131-I was evenly distributed in the liver, and there was no correlation between the cause of even distribution with age(OR=0.961, P = 0.939), previous open surgery history(OR=3.547,P= 0.128), previous history of interventional therapy(OR=0.140,P = 0.072), the interval between the last interventional surgery and the Licartin treatment(OR=0.858,P = 0.883), or the choice of the perfusion artery in the Licartin treatment (OR=1.489,P = 0.419). In 14 cases (34.1%), there was higher aggregation in the tumor than in the normal liver, which was related to previous interventional surgery (OR=7.443,P = 0.043). In 13 cases (31.7%), there was lower aggregation in the tumor than in the normal liver, which was related to the selected vessels in the Licartin perfusion (OR=0.23,P = 0.013).ConclusionThe effective aggregation of 131-I in the liver, even in tumors, the previous history of TACE, and the choice of vessels in the Licartin infusion might be the factors influencing the distribution of 131-I in the liver during hepatic artery infusion of Licartin in combination with TACE therapy.

01 Aug 2019·Clinics and Research in Hepatology and Gastroenterology

A meta-analysis of the efficacy and safety of iodine [131I] metuximab infusion combined with TACE for treatment of hepatocellular carcinoma

Article

Author: Li, Jiaping ; Cui, Wei ; Zhao, Yue ; Wu, Yanqin ; Fan, Wenzhe ; Yao, Wang ; Lu, Mingjian ; Wang, Yu

OBJECTIVESTo compare the efficacy and safety of combination iodine [¹³¹I] metuximab infusion and transcathether arterial chemoembolization (TACE) with those of TACE-alone for hepatocellular carcinoma (HCC).MATERIALS AND METHODSPubMed, Cochrane Library, Embase, Web of Science, China Biology Medicine, China Science and Technology Journal Database, Wan Fang Data, and Chinese knowledge resource integrated databases were used for the literature search regarding controlled clinical trials comparing combination TACE and iodine [¹³¹I] metuximab infusion with TACE-alone for HCC treatment before February 1, 2016. The Jadad system evaluation method for research quality and RevMan 5.0 software were used for the meta-analysis.RESULTSIn total, 1302 patients from 10 studies were included. The meta-analysis showed that the combination TACE and iodine [¹³¹I] metuximab infusion treatment for HCC was more effective than TACE alone, including 6-month survival (odds ratio [OR] = 2.05, 95% confidence interval [CI]: 1.41-2.98, P = 0.0002), 1-year survival (OR = 1.90, 95% CI: 1.41-2.55, P < 0.00001), and the total response rate (OR = 2.91, 95% CI: 2.08-4.07, P < 0.00001). Nine studies reported adverse reactions, mainly comprising poor appetite, nausea, vomiting, and abdominal discomfort. Fever, chills, and bone marrow suppression were more common in the combined treatment group, but abnormal liver function was not different between the two treatment groups. There was no report on serious complications or death directly related to either treatment.CONCLUSIONSCompared with TACE alone, the combination of TACE with iodine [¹³¹I] metuximab infusion for treating unresectable HCC may improve local efficacy and overall survival in these types of patients.

04 Sep 2018·Zhonghua yi xue za zhi

[Efficacy and safety of licartin with repeated administration in treatment of HCC patients after liver transplantation].

Article

Author: L Qin ; J P Li ; J Li ; J Shen ; E C Ding

Objective: To evaluate the efficacy and adverse reactions of licartin with repeated administration in treatment of hepatocellular carcinoma (HCC) patients after liver transplantation. Methods: Clinical data of 60 patients after liver transplantation with licartin in Tianjin First Central Hospital from December 2012 to December 2016 were collected and analyzed.The patients were divided into A group(received single therapy, n=45)and B group(received repeated therapy with equal or greater than twice, n=15). The results of blood routine examination, liver function and thyroid function between the two groups(1 week before treatment, 2, 4 and 8 weeks after treatment) were compared. Survival time and adverse reactions were statistically analyzed. Results: There was no significant statistical difference on age, gender and AFP between the two groups(all P>0.05). Compared to baseline level 1 week before treatment, platelet levels were reduced 2 weeks after treatment, and gradually recovered to baseline level at 8 weeks(F=50.42 and 61.71, all P<0.05); 4 weeks after treatment, the alanine aminotransferase and total bilirubin levels were increased to a certain extent and recovered to baseline at 8 weeks(F=5.42 and 3.39, 8.95 and 6.84, all P<0.05). Thyroid function injury ratio for the two groups were 8.9% and 8.6%. No serious adverse reactions occurred, and mild adverse reactions could be tolerated with spontaneous remission or symptomatic treatment. There was no significant statistical difference between the two groups(χ²=0.459-1.0, all P>0.05). The median survival time was 34.0 months for A group, the 6-, 12-, 18-, 24-, 36- and 48-month overall survival rates for the two groups were 93.3%, 86.6%, 73.3%, 62.2%, 48.9%, 33.3% and 100%, 93.3%, 86.7%, 80.0%, 66.7%, 66.7%, respectively (χ²=4.324, P=0.038). HCC in situ recurrence rate for the two groups were 15.6% and 13.3%(χ²=1.0, P=0.601). The incidence of hepatocellular metastasis for the two groups were 22.2% and 20.0%(χ²=1.0, P=0.585). Conclusion: Repeated licartin administration could prevent HCC recurrence and prolong survival with satisfactory safety.

100 Deals associated with Iodine[131I] Metuximab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hepatocellular Carcinoma	CN	Chengdu Huasun Biotechnology Co. Ltd.	12 Oct 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed \| Int J Radiat Oncol Biol Phys Manual	Phase 2	Hepatocellular Carcinoma	106	iodine metuximab	(ievaultmeo) = jvvjepqfeq ocnfsigodz (sikdomcsje ) View more	Positive	01 Jun 2006